A significant unmet need exists for effective, low-toxicity early treatment in IDH-mutant gliomas, especially for younger patients and those with grade 2 tumors. Voranigo, an IDH1 and IDH2 inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results